Trafalgar International (GCAN) EBITDA (2017 - 2026)
Trafalgar International (GCAN) posted EBITDA of -$33376.0 for Q1 2026, up 37.97% on a QoQ basis from -$53806.0 in Q4 2025, and up 23.34% year-over-year from -$27060.8 in Q1 2025.
Powered by 
Analysis
Trafalgar International (GCAN) EBITDA (2017 - 2026) Analysis & Trends
Trafalgar International has reported EBITDA for 10 years, with the latest figure at -$33376.0 in Q1 2026.
- On a quarterly basis, EBITDA rose 23.34% year-over-year to -$33376.0 in Q1 2026; TTM through Mar 2026 was -$172845.0, a 7.45% decrease from a year earlier, with the FY2025 full-year figure at -$183005.0, down 17.1% from the prior year.
- EBITDA was -$33376.0 for Q1 2026 at Trafalgar International, up from -$53806.0 in the prior quarter.
- The five-year high for EBITDA was -$33376.0 in Q1 2026, with the low at -$53806.0 in Q4 2025.
- Average EBITDA over 5 years is -$42650.4, with a median of -$42267.0 recorded in 2022.
- The sharpest annual moves came in 2022 and 2025: EBITDA jumped 64.81% in 2022, then sank 43.01% in 2025.
- Over 5 years, EBITDA stood at -$42267.0 in 2022, then retreated by 4.16% to -$44027.0 in 2023, then gained by 14.54% to -$37625.0 in 2024, then tumbled by 43.01% to -$53806.0 in 2025, then jumped by 37.97% to -$33376.0 in 2026.
- The last three EBITDA figures came in at -$33376.0 (Q1 2026), -$53806.0 (Q4 2025), and -$37412.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 7.14 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | 6.43 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | -584.00 Mn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 4.75 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 4.27 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 1.22 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | -505.13 Mn |
| 8 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 697.90 Mn |
| 9 | United Therapeutics | 20.81 Bn | 18.15 Bn | 683.80 Mn | 330.80 Mn |
| 10 | Trafalgar International | 217,335.05 | 217,335.05 | - | -33,376.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -33,376.00 |
| Dec 31, 2025 | -53,806.00 |
| Sep 30, 2025 | -37,412.00 |
| Jun 30, 2025 | -48,251.00 |
| Mar 31, 2025 | -43,536.00 |
| Dec 31, 2024 | -37,625.00 |
| Sep 30, 2024 | -40,443.00 |
| Jun 30, 2024 | -39,257.00 |
| Mar 31, 2024 | -38,951.00 |
| Dec 31, 2023 | -44,027.00 |
| Sep 30, 2023 | -50,465.00 |
| Jun 30, 2023 | -41,404.00 |
| Mar 31, 2023 | -39,468.00 |
| Dec 31, 2022 | -42,267.00 |
| Sep 30, 2022 | -49,304.00 |
| Jun 30, 2022 | -43,034.00 |
| Mar 31, 2022 | -42,430.00 |
| Dec 31, 2021 | -120,102.00 |
| Sep 30, 2021 | -74,338.00 |
| Jun 30, 2021 | -62,474.00 |